scholarly journals SUN-041 THE CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH END STAGE KIDNEY DISEASE SECONDARY TO MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS IN AUSTRALIA AND NEW ZEALAND

2019 ◽  
Vol 4 (7) ◽  
pp. S170
Author(s):  
G. WILSON ◽  
Y. Cho ◽  
A. Teixeira-Pinto ◽  
N. Isbel ◽  
S. Campbell ◽  
...  
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
Membranoproliferative Glomerulonephritis ◽  
End Stage Kidney Disease ◽  
End Stage

scholarly journals Absolute risk and risk factors for stroke mortality in patients with end-stage kidney disease (ESKD): population-based cohort study using data linkage

BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e026263 ◽  
Author(s):  
Nicole Louise De La Mata ◽  
Maria Alfaro-Ramirez ◽  
Patrick J Kelly ◽  
Philip Masson ◽  
Rustam Al-Shahi Salman ◽  
...  
Keyword(s):  
Risk Factors ◽  
New Zealand ◽  
Kidney Disease ◽  
Cerebrovascular Disease ◽  
Cumulative Incidence ◽  
Data Linkage ◽  
Polycystic Kidney ◽  
End Stage Kidney Disease ◽  
End Stage ◽  
Stroke Death

IntroductionPeople with end-stage kidney disease (ESKD) have up to 30-fold higher risk of stroke than the general population.ObjectiveTo determine risk factors associated with stroke death in the ESKD population.MethodsWe identified all patients with incident ESKD in Australia (1980–2013) and New Zealand (1988–2012) from the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) registry. We ascertained underlying cause of death from data linkage with national death registries and risk factors from ANZDATA. Using a competing risks multivariable regression model, we estimated cumulative incidence of stroke and non-stroke deaths, and risk factors for stroke deaths (adjusted sub-HR, SHR).ResultsWe included 60 823 people with ESKD. There were 941 stroke deaths and 33 377 non-stroke deaths during 381 874 person-years of follow-up. Overall, the cumulative incidence of stroke death was 0.9% and non-stroke death was 36.8% 5 years after starting ESKD treatment. The risk of stroke death was higher at older ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 1.41, 95% CI 1.21 to 1.64), in people with cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD caused by hypertensive/renovascular disease (SHR 1.39, 95% CI 1.09 to 1.78) or polycystic kidney disease (SHR 1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) and receiving dialysis (transplant vs haemodialysis SHR 0.27, 95% CI 0.09 to 0.84).ConclusionPatients with ESKD with higher risk of stroke death are older, women, with cerebrovascular disease, with hypertensive/renovascular or polycystic kidney disease cause of ESKD, with earlier year of ESKD treatment and receiving dialysis. These groups may benefit from targeted stroke prevention interventions.

scholarly journals Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Gregory J. Wilson ◽  
Yeoungjee Cho ◽  
Armando Teixiera-Pinto ◽  
Nicole Isbel ◽  
Scott Campbell ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kidney Disease ◽  
Membranoproliferative Glomerulonephritis ◽  
Patient Survival ◽  
Disease Recurrence ◽  
Allograft Survival ◽  
End Stage Kidney Disease ◽  
Kidney Replacement Therapy ◽  
Allograft Loss ◽  
End Stage

Abstract Background Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end stage kidney disease (ESKD) and the clinical outcomes of patients with MPGN who commence kidney replacement therapy have not been comprehensively studied. Methods All adult patients with ESKD due to glomerulonephritis commencing kidney replacement therapy in Australia and New Zealand from January 1, 1996 to December 31, 2016 were reviewed. Patients with ESKD due to MPGN were compared to patients with other forms of glomerulonephritis. Patient survival on dialysis and following kidney transplantation, kidney recovery on dialysis, time to transplantation, allograft survival, death-censored allograft survival and disease recurrence post-transplant were compared between the two groups using Kaplan Meier survival curves and Cox proportional hazards regression. Results Of 56,481 patients included, 456 (0.8%) had MPGN and 12,660 (22.4%) had another form of glomerulonephritis. Five-year patient survival on dialysis and following kidney transplantation were similar between patients with ESKD from MPGN and other forms of glomerulonephritis (Dialysis: 59% vs. 62% p = 0.61; Transplant: 93% vs. 93%, p = 0.49). Compared to patients with other forms of glomerulonephritis, patients with MPGN had significantly poorer 5-year allograft survival (70% vs. 81% respectively, p = 0.02) and death censored allograft survival (74% vs. 87%, respectively; p < 0.01). The risk of disease recurrence was significantly higher in patients with MPGN compared to patients with other glomerulonephritidites (18% vs. 5%; p < 0.01). In patients with MPGN who had allograft loss, patients with MPGN recurrence had a significantly shorter time to allograft loss compared to patients with MPGN who had allograft loss due to any other cause (median time to allograft loss 3.2 years vs. 4.4 years, p < 0.01). Conclusions Compared with other forms of glomerulonephritis, patients with MPGN experienced comparable rates of survival on dialysis and following kidney transplantation, but significantly higher rates of allograft loss due to disease recurrence.

Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand

2009 ◽  
Vol 24 (9) ◽  
pp. 1719-1726 ◽  
Author(s):  
Nigel I. T. Orr ◽  
Stephen P. McDonald ◽  
Steven McTaggart ◽  
Paul Henning ◽  
Jonathan C. Craig
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
End Stage Kidney Disease ◽  
End Stage

Cause of death for people with end-stage kidney disease withdrawing from treatment in Australia and New Zealand

2020 ◽  
Author(s):  
Victor Khou ◽  
Nicole L De La Mata ◽  
Rachael L Morton ◽  
Patrick J Kelly ◽  
Angela C Webster
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
Confidence Interval ◽  
Treatment Modality ◽  
Causes Of Death ◽  
Mortality Rates ◽  
Service Planning ◽  
Treatment Withdrawal ◽  
End Stage Kidney Disease ◽  
End Stage

Abstract Background Withdrawal from renal replacement therapy is common in patients with end-stage kidney disease (ESKD), but end-of-life service planning is challenging without population-specific data. We aimed to describe mortality after treatment withdrawal in Australian and New Zealand ESKD patients and evaluate death-certified causes of death. Methods We performed a retrospective cohort study on incident patients with ESKD in Australia, 1980–2013, and New Zealand, 1988–2012, from the Australian and New Zealand Dialysis and Transplant registry. We estimated mortality rates (by age, sex, calendar year and country) and summarized withdrawal-related deaths within 12 months of treatment modality change. Certified causes of death were ascertained from data linkage with the Australian National Death Index and New Zealand Mortality Collection database. Results Of 60 823 patients with ESKD, there were 8111 treatment withdrawal deaths and 26 207 other deaths over 381 874 person-years. Withdrawal-related mortality rates were higher in females and older age groups. Rates increased between 1995 and 2013, from 1142 (95% confidence interval 1064–1226) to 2706/100 000 person-years (95% confidence interval 2498–2932), with the greatest increase in 1995–2006. A third of withdrawal deaths occurred within 12 months of treatment modality change. The national death registers reported kidney failure as the underlying cause of death in 20% of withdrawal cases, with other causes including diabetes (21%) and hypertensive disease (7%). Kidney disease was not mentioned for 18% of withdrawal patients. Conclusions Treatment withdrawal represents 24% of ESKD deaths and has more than doubled in rate since 1988. Population data may supplement, but not replace, clinical data for end-of-life kidney-related service planning.

Medication Exposure and Health Outcomes in Older Patients with End-Stage Kidney Disease: A Prospective Study Undertaken in New Zealand

Drugs & Aging ◽  
2018 ◽  
Vol 35 (11) ◽  
pp. 1005-1015 ◽  
Author(s):  
Sashika Samaranayaka ◽  
Robert J. Walker ◽  
Ari Samaranayaka ◽  
Sarah Derrett ◽  
John W. B. Schollum
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
Health Outcomes ◽  
Prospective Study ◽  
Older Patients ◽  
End Stage Kidney Disease ◽  
Medication Exposure ◽  
End Stage ◽  
A Prospective Study
Sign in / Sign up

Export Citation Format

Share Document